Diasorin receives 510(K) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX
Diasorin announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the second of its 3 multiplex molecular panels for blood culture pathogen identification on the LIAISON PLEX system.
Following clearance in March 2024 for the LIAISON PLEX Respiratory Flex Assay, and in June 2024 of the LIAISON PLEX Yeast Blood Culture Assay, Diasorin expanded the menu of multiplex blood culture panels for the microbiological diagnosis of bloodstream infections on the new LIAISON PLEX system.
The LIAISON PLEX Gram-Negative Blood Culture Assay:
· is designed to identify 27 targets, including 19 gram-negative bacteria and 8 relevant resistance gene targets;
· complements standard-of-care workflow;
· reduces operational spending.
